Pharmaceutical company Pfizer, with whom Canada has signed an agreement, hopes to know next month whether its experimental vaccine against COVID-19 is working and remains on course for availability before the end of the year, at least in the United States. .
“We have a good chance, I would say more than 60%, of knowing if the product works by the end of October” declared the big boss of the American company, Albert Bourla, on the program. Face the Nation from the CBS channel.
Mr. Bourla clarified that this is the “best scenario” while qualifying that “of course, that does not mean that it will work. This means that we will know if it is working. “
If it turns out to be sure and effective, a race against time would then begin to have the vaccine approved by the regulatory authorities, and to make it available.
Albert Bourla estimated that it was “likely” that the vaccine will be offered in the United States before the end of the year, repeating a wish already expressed by his company this summer.
A positive outcome would also bode well for Canadians, as Pfizer has committed to providing Canada with 20 million doses in the event that its vaccine is confirmed to be effective.
The Canadian government has signed similar agreements with the designers of three other coronavirus vaccines in development, to secure up to 190 million doses.
During the interview, however, Mr. Bourla only commented on a possible distribution in the United States.
This distribution is also likely to be “very gradual”, tempered, on the same show, a member of the board of directors of Pfizer and former commissioner of the FDA, the American organization which approves drugs.
The first doses of Pfizer’s vaccine, if approved, would surely be reserved for the most vulnerable people and front-line health workers, said Dr.r Scott Gottlieb.
“Most people” would therefore not have access before next year, access to the general public can be expected “perhaps in the first quarter of 2021, probably in the first half of 2021”, according to him.
Pfizer and its German partner BioNTech launched at the end of July the final phase (phase 2/3) of the clinical trials of their experimental vaccine against COVID-19 called BNT162.
It is currently being tested on nearly 30,000 people – out of a target of 44,000 volunteers – in numerous sites around the world.
Around the world, there are nine candidate vaccines in the final stage of clinical trials.